Immunologische Tumortherapie

详细信息    查看全文

• 作者：Dr. K. Dietrich ; M. Theobald
• 关键词：Tumorvakzinen ; Immunmodulation ; Adoptiver Transfer immunologischer Effektoren ; Immuncheckpoint ; Inhibition ; Chim盲re Antigenrezeptoren ; Cancer vaccines ; Immunomodulation ; Immunological effectors ; adoptive transfer ; Immune checkpoint ; blockade ; Antigen receptors ; chimeric
• 刊名：Der Internist
• 出版年：2015
• 出版时间：August 2015
• 年：2015
• 卷：56
• 期：8
• 页码：907-917
• 全文大小：850 KB
• 参考文献：1.Maus MV, Grupp SA, Porter DL et聽al (2014) Antibody-modified T聽cells: CARs take the front seat for hematologic malignancies. Blood 123:2625鈥?635PubMed Central PubMed View Article
  2.Palucka K, Banchereau J (2012) Cancer immunotherapy via dendritic cells. Nat Rev Cancer 12:265鈥?77PubMed Central PubMed View Article
  3.Kantoff PW, Higano CS, Shore ND et聽al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N聽Engl J Med 363:411鈥?22
  4.Weber JS (2014) Current perspectives on immunotherapy. Semin Oncol 41(Suppl聽5):S14鈥揝29PubMed View Article
  5.Disis ML (2014) Mechanism of action of immunotherapy. Semin Oncol 41(Suppl聽5):S3鈥揝13PubMed View Article
  6.Browning MJ (2013) Antigen presenting cell/tumor cell fusion vaccines for cancer immunotherapy. Hum Vaccin Immunother 9:1545鈥?548PubMed Central PubMed View Article
  7.Chiang CL, Kandalaft LE, Coukos G (2011) Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines. Int Rev Immunol 30:150鈥?82PubMed View Article
  8.Makkouk A, Weiner GJ (2015) Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge. Cancer Res 75:5鈥?0PubMed View Article
  9.Mellman I, Coukos G, Dranoff G (2011) Cancer immunotherapy comes of age. Nature 480:480鈥?89PubMed Central PubMed View Article
  10.Sahin U, Karik贸 K, T眉reci 脰 (2014) mRNA-based therapeutics 鈥?developing a new class of drugs. Nat Rev Drug Discov 13:759鈥?80PubMed View Article
  11.Kreiter S, Vormehr M, Roemer N van de et聽al (2015) Mutant MHC class聽II epitopes drive therapeutic immune responses to cancer. Nature 520:692鈥?96PubMed View Article
  12.Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252鈥?64PubMed View Article
  13.Hodi FS, O鈥橠ay SJ, McDermott DF et聽al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N聽Engl J Med 363:711鈥?23
  14.Hamid O, Robert C, Daud A et聽al (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N聽Engl J Med 369:134鈥?44
  15.Robert C, Long GV, Brady B et聽al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N聽Engl J Med 372:320鈥?30
  16.Curti BD, Kovacsovics-Bankowski M, Morris N et聽al (2013) OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res 73:7189鈥?198PubMed Central PubMed View Article
  17.Vanneman M, Dranoff G (2012) Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 12:237鈥?51PubMed Central PubMed View Article
  18.Rizvi NA, Hellmann MD, Snyder A et聽al (2015) Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348:124鈥?28PubMed View Article
  19.Duong CMP, Yong CSM, Kershaw MH et聽al (2015) Cancer immunotherapy utilizing gene-modified T聽cells: from the bench to the clinic. Mol Immunol (im Druck). http://鈥媎x.鈥媎oi.鈥媜rg/鈥?0.鈥?016/鈥媕.鈥媘olimm.鈥?014.鈥?2.鈥?09
  20.Weidle UH, Kontermann RE, Brinkmann U (2014) Tumor-antigen-binding bispecific antibodies for cancer treatment. Semin Oncol 41:653鈥?60PubMed View Article
  21.Topp MS, G枚kbuget N, Stein AS et聽al (2015) Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase聽2 study. Lancet Oncol 16:57鈥?6PubMed View Article
  22.Huehls AM, Coupet TA, Sentman CL (2015) Bispecific T-cell engagers for cancer immunotherapy. Immunol Cell Biol 93:290鈥?96PubMed View Article
  23.Topalian SL, Solomon D, Avis FP et聽al (1988) Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J聽Clin Oncol 6:839鈥?53
  24.Dudley ME, Yang JC, Sherry R et聽al (2008) Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J聽Clin Oncol 26:5233鈥?239
  25.Rosenberg SA, Yang JC, Sherry RM et聽al (2011) Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17:4550鈥?557PubMed Central PubMed View Article
  26.Morgan RA, Dudley ME, Wunderlich JR et聽al (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314:126鈥?29PubMed Central PubMed View Article
  27.Stanislawski T, Voss RH, Lotz C et聽al (2001) Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol 2:962鈥?70PubMed View Article
  28.Parkhurst MR, Joo J, Riley JP et聽al (2009) Characterization of genetically modified T-cell receptors that recognize the CEA:691鈥?99 peptide in the context of HLA-A2.1 on human colorectal cancer cells. Clin Cancer Res 15:169鈥?80PubMed Central PubMed View Article
  29.Robbins PF, Morgan RA, Feldman SA et聽al (2011) Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J聽Clin Oncol 29:917鈥?24
  30.Kuball J, Schmitz FW, Voss RH et聽al (2005) Cooperation of human tumor-reactive CD4+ and CD8+ T聽cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. Immunity 22:117鈥?29PubMed View Article
  31.Kershaw MH, Westwood JA, Slaney CY et聽al (2014) Clinical application of genetically modified T聽cells in cancer therapy. Clin Transl Immunology 3:e16PubMed Central PubMed View Article
  
• 作者单位：Dr. K. Dietrich (1)
  M. Theobald (1)
  
  1. III. Medizinische Klinik und Poliklinik, Universit盲tsmedizin Mainz, Langenbeckstr. 1, 55131, Mainz, Deutschland
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Cardiology
  General Practice and Family Medicine
  Internal Medicine
  Gastroenterology
  Hepatology
  Nephrology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-1289

文摘

Tumor cells could fundamentally be recognized and eliminated by the immune system but malignant cells are able to escape the immune surveillance system. The idea of immunotherapy of cancer is to activate, modulate and amplify the host immune response or to genetically equip the immune repertoire of patients with anti-tumor specificities and effectors. In recent years, a variety of promising immunotherapy strategies have been developed, such as bispecific, multispecific and immunoregulatory antibodies, gene-modified T lymphocytes and tumor vaccines. Some drugs have already been approved and others are available for patients in clinical trials. This article presents the current anti-tumor immune strategies and their molecular basis. Even though further research is needed in some areas, such as the establishment of biomarkers for targeted therapy, duration of therapeutic activity and compatibility of combined strategies, cancer immunotherapy is likely to be a key component in oncological treatment concepts in the very near future.